We propose that the observed and desirable anti-tumour effects of TESTIN expression in B ALL and other tumour cells highlight the need to investigate its protein partners and their associated pathways and that this may reveal potential, novel therapeutic targets. Here, TES is linked to acute lymphoblastic leukemia.